ARTH - Arch Therapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.2320
-0.0071 (-2.97%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.2391
Open0.2440
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2250 - 0.2440
52 Week Range0.1210 - 0.4350
Volume278,910
Avg. Volume327,761
Market Cap43.584M
Beta (5Y Monthly)0.30
PE Ratio (TTM)N/A
EPS (TTM)-0.0270
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.63
  • GlobeNewswire

    Arch Therapeutics to Provide Corporate Update at Biotech Showcase™ 2020 on January 13th, 2020

    Chief Executive Officer, Terrence W. Norchi, MD, is scheduled to present on Monday, January 13 at 4:00 PM PST in Franciscan A – Ballroom Level. Dr. Norchi and Mr. Richard Davis, Chief Financial Officer, will be available to meet with investors who are registered to attend the conference. Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care.

  • GlobeNewswire

    Arch Therapeutics Announces $2.5 Million Registered Direct Offering

    Arch Therapeutics, Inc. (ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase in a registered direct offering of 14,285,714 shares of its common stock and warrants to purchase up to 14,285,714 shares of its common stock, at a combined purchase price of $0.175 per share and related warrant. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds of the offering are expected to be approximately $2.5 million, before deducting the placement agent’s fees and other estimated offering expenses.

  • GlobeNewswire

    Arch Therapeutics Provides Corporate Update at the 2nd Annual LD Micro Big Apple Conference in Manhattan, NY

    Arch Therapeutics, Inc. (ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, is scheduled to provide a corporate update today at the 2nd Annual LD Micro Big Apple Conference in Manhattan, NY. The corporate update, which will be provided by Chief Executive Officer, Terrence W. Norchi, MD, will include the highlights below. Arch is actively engaged with a number of companies across several geographic jurisdictions around the world on potential partnership opportunities to commercialize AC5.

  • GlobeNewswire

    Arch Therapeutics to Provide Corporate Update at the H.C. Wainwright 21st Annual Global Investment Conference

    FRAMINGHAM, Mass., Sept. 03, 2019 -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care.

  • GlobeNewswire

    Arch Therapeutics Announces AC5 Self-Assembling Peptide Technology Platform Demonstrates Antimicrobial Activity in Two Studies and Provides CE Marking Status Update for AC5™ Topical Hemostat

    Arch Therapeutics, Inc. (ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, announced today the results of two studies supporting the underlying antimicrobial properties of the Company’s AC5TM self-assembling peptide technology platform (AC5). Arch also provided an update on the status of the CE Marking process for AC5TM Topical Hemostat in the European Union. The first study used an in vitro bioburden model in which AC5 and control media were exposed to the same levels of three common and potentially pathogenic wound bacteria: Staphylococcus epidermidis (SE), methicillin-susceptible Staphylococcus aureus (MSSA), and methicillin-resistant Staphylococcus aureus (MRSA).

  • GlobeNewswire

    Arch Therapeutics to Provide Corporate Update at the 9th Annual LD Micro Invitational

    FRAMINGHAM, Mass., May 30, 2019 -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,.

  • GlobeNewswire

    Arch Therapeutics, Inc. $2.8 Million Registered Direct Offering

    Arch Therapeutics, Inc. (ARTH)(“Arch” or the “Company”), a developer of novel liquid, gel and solid hemostatic and wound care devices, today announced the pricing of registered direct offering of approximately 8.6 million units, each unit consisting of a share of the Company’s common stock, and a Series H Warrant (“Series H Warrant”) to purchase 1 (one) share of our common stock for the combined purchase price of $0.325 per unit. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to obtain required regulatory approvals, our ability to produce commercial quantities of our products within projected timeframes, our ability to develop and commercialize products based on our technology platform, and market conditions.

  • GlobeNewswire

    Arch Therapeutics Announces Attendance at 2019 Symposium on Advanced Wound Care Conference (SAWC) and Release of a New AC5TM Topical Gel Video

    FRAMINGHAM, Mass., April 24, 2019 -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of products for dermal science and biosurgical applications,.

  • GlobeNewswire

    Arch Therapeutics to Provide Corporate Update at the 31st Annual ROTH Conference

    FRAMINGHAM, Mass., March 11, 2019 -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care.

  • GlobeNewswire

    Arch Therapeutics to Provide Corporate Update at the 2019 BIO CEO & Investor Conference

    FRAMINGHAM, Mass., Feb. 05, 2019 -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,.